Literature DB >> 15642425

The surgical management of incidental gallbladder carcinoma.

E Yildirim1, O Celen, K Gulben, U Berberoglu.   

Abstract

AIMS: To report the surgical management of carcinoma of the gallbladder.
METHODS: A retrospective study in 65 patients who underwent simple (SC) or extended (EC) cholecystectomy for gallbladder carcinoma.
RESULTS: 28 patients underwent extended cholecystectomy (EC) and 37 had simple cholecystectomy (SC). The multivariate analysis showed that lymph-node status (positive vs negative, p=0.001, Hazard Ratio [HR]:14.2, 95% Confidence Interval [CI]:3.1-62.8) and type of surgery (SC vs EC, p=0.01, HR:10.2, 95% CI:1.7-62.8) were the most important prognostic factors related to death. This analysis indicated that EC in those with pT(2) or pT(3) was associated with a reduce hazard of death by 90% in the follow-up period.
CONCLUSIONS: In gallbladder cancer patients who diagnose after simple cholecystectomy, those with pT(1) with clear margins need no further surgery. In patients with pT(2) or pT(3) incidental carcinoma, the completion radical re-operation is the only chance for long-term survival.

Entities:  

Mesh:

Year:  2005        PMID: 15642425     DOI: 10.1016/j.ejso.2004.09.006

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  25 in total

1.  Early gallbladder carcinoma has a favorable outcome but Rokitansky-Aschoff sinus involvement is an adverse prognostic factor.

Authors:  Juan C Roa; Oscar Tapia; Carlos Manterola; Miguel Villaseca; Pablo Guzman; Juan Carlos Araya; Pelin Bagci; Burcu Saka; Volkan Adsay
Journal:  Virchows Arch       Date:  2013-09-11       Impact factor: 4.064

2.  Comparative analysis between clinical outcomes of primary radical resection and second completion radical resection for T2 gallbladder cancer: single-center experience.

Authors:  Seong Yeon Cho; Sang-Jae Park; Seong Hoon Kim; Sung-Sik Han; Young-Kyu Kim; Kwang-Woong Lee
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

3.  Routine histology of cholecystectomy specimens is unnecessary.

Authors:  C M Oommen; A Prakash; J C Cooper
Journal:  Ann R Coll Surg Engl       Date:  2007-10       Impact factor: 1.891

4.  Lymphatic invasion: an important prognostic factor for stages T1b-T3 gallbladder cancer and an indication for additional radical resection of incidental gallbladder cancer.

Authors:  Kohei Shibata; Hiroki Uchida; Kentaro Iwaki; Seiichiro Kai; Masayuki Ohta; Seigo Kitano
Journal:  World J Surg       Date:  2009-05       Impact factor: 3.352

5.  Benefit of extended radical surgery for incidental gallbladder carcinoma.

Authors:  Junpei Yamaguchi; Yuji Kaneoka; Atsuyuki Maeda; Yuichi Takayama; Shunsuke Onoe; Masatoshi Isogai
Journal:  Surg Today       Date:  2015-06-17       Impact factor: 2.549

Review 6.  Clinical characteristics of incidental or unsuspected gallbladder cancers diagnosed during or after cholecystectomy: a systematic review and meta-analysis.

Authors:  Kui Sun Choi; Sae Byeol Choi; Pyoungjae Park; Wan Bae Kim; Sang Yong Choi
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

7.  Histopathological examination of specimen following cholecystectomy: Are we accepting resect and discard?

Authors:  Sean M Wrenn; Peter W Callas; Wasef Abu-Jaish
Journal:  Surg Endosc       Date:  2016-06-20       Impact factor: 4.584

8.  Gallbladder cancer.

Authors:  Sanjeev Misra; Arun Chaturvedi; N C Misra
Journal:  Curr Treat Options Gastroenterol       Date:  2006-04

9.  Revision surgery for incidental gallbladder cancer: factors influencing operability and further evidence for T1b tumours.

Authors:  P J Shukla; G Barreto; A Kakade; S V Shrikhande
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

10.  Does PET-CT scan have a role prior to radical re-resection for incidental gallbladder cancer?

Authors:  Parul J Shukla; Savio G Barreto; Supreeta Arya; Shailesh V Shrikhande; Rohini Hawaldar; Nilendu Purandare; Venkatesh Rangarajan
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.